Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT03972228

Microdevice for Evaluating Drug Response in Site in Lung Lesions

Pilot Study of Microdevice for Evaluating Drug Response in Site in Lung Lesions

Sponsor: Massachusetts General Hospital

Interventions Microdevice loaded with 19 chemotherapeutic agents

Updated 6 times since 2019 Last updated: Sep 16, 2021 Started: Oct 1, 2018 Primary completion: Sep 1, 2021 Completion: Sep 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Lung Cancer and Lung Tumor and is currently completed. Massachusetts General Hospital leads this study, which shows 6 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Oct 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1

Status: Recruiting → Completed
Jan 2021 — Oct 2021 [monthly]

Recruiting EARLY_PHASE1
Aug 2020 — Jan 2021 [monthly]

Recruiting EARLY_PHASE1

▶ Show 1 earlier version

Jul 2019 — Aug 2020 [monthly]

Recruiting EARLY_PHASE1

First recorded

Oct 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Massachusetts General Hospital
Oliver Jonas

Data source: Brigham and Women's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States